La Roche-Posay announces its first-ever safety guarantee on skincare product for atopic newborns from day 1 of life
31 Jan, 2018, 06:05 ET
Lipikar Baume AP+ and Lipikar Syndet AP+ are guaranteed with optimal skin tolerance for newborns
MONTREAL, Jan. 31, 2018 /CNW/ - As the first brand recommended by dermatologists in Canada, La Roche-Posay, now offers its first-ever safety guarantee on its Lipikar AP+ and Lipikar Syndet AP+ products for atopic, eczema prone newborns, clinically proven to be safe to use from the first day of life.
"Our mission at La Roche-Posay is to provide a better life for sensitive skin and that applies to all members of the family, even our precious newborns," says Emma Kindler, General Manager of La Roche-Posay Canada. "We pride ourselves on making no compromise on efficacy or safety, and this new claim strengthens our commitment with a new emblematic safety guarantee for newborns, especially those with atopic eczema-prone skin. Now families across Canada can feel confident using Lipikar Baume AP+ or Lipikar Syndet AP+ on their babies, which we hope will improve the quality of life for Canadian families."
Clinically proven tolerance on newborn skin
In recent clinic tests, Lipikar Baume AP+and Lipikar Syndet AP+ have shown significant tolerance results on children and babies. Both products have been tested on newborns, in a clinical study and under pediatric control, proving their optimal safety1.
Additional clinical studies have demonstrated that using emollients as the first three weeks of life reduces the risk of developing eczema-prone skin2. Conducted on 124 neonates at high risk for atopic dermatitis, the results showed that emollient therapy from birth represents a feasible, safe, and effective way to prevent atopic eczema.
Atopic eczema is a chronic inflammatory skin disease that has reached epidemic proportion in children worldwide and is increasing in prevalence. Children suffering from this condition, experience unbearable itch along with inflamed, cracked, and often infected skin lesions.
The LIPIKAR AP+ routine, recommended by dermatologists, soothes and calms the atopic eczema-prone skin, thanks to its lipid-replenishing, anti-irritation, anti-scratching, anti-itch properties
LIPIKAR BAUME AP+ - Spaces out flare-ups of severe dryness
- 100% of users found the product easy to apply
- 97% of users found the product gentle on skin, leaving it comfortable
- 93% of users found the product absorbed well
LIPIKAR SYNDET AP+ - Reduces severe dryness beginning with the shower
- 97% of users found the product washed easily and left skin comfortable when rinsed off
- 93% of users found the product respected the balance of skin
- 91% of users found the product left the skin hydrated and nourished
ABOUT LA ROCHE-POSAY
La Roche-Posay is a division of L'Oréal Canada, a wholly-owned subsidiary of L'Oréal Group, the largest cosmetics company in the world. Headquartered in Montreal, L'Oréal Canada had sales of $1.07 billion in 2014 and employs more than 1,200 people. The company's prestigious portfolio of 35 brands encompasses all aspects of beauty.
"Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention" JALLERGY CLIN IMMUNOL, VOLUME 134, NUMBER 4
Internal study conducted on 40 newborns, 0-1 month old, under dermatologic and pediatric control. 1 dedicated evaluation per product. Application on face and body at least once a day during 4 weeks.
SOURCE La Roche-Posay
For further information: Krystal Stukas, The Colony Project on behalf of La Roche-Posay, T: 705.896.4427, E: [email protected]
Share this article